News for Centessa Pharmaceuticals PLC Stock (CNTA)

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Zacks Investment Research • 12/26/23

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • 12/13/23

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

GlobeNewsWire • 12/10/23

Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?

Zacks Investment Research • 12/05/23

Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

Zacks Investment Research • 11/16/23

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

GlobeNewsWire • 11/13/23

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

GlobeNewsWire • 11/02/23

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

GlobeNewsWire • 10/31/23

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

GlobeNewsWire • 10/25/23

Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets

Seeking Alpha • 09/14/23

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

Zacks Investment Research • 09/04/23

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

GlobeNewsWire • 08/23/23

Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated

Seeking Alpha • 08/17/23

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

GlobeNewsWire • 08/14/23

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

GlobeNewsWire • 07/10/23

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

GlobeNewsWire • 05/22/23

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

GlobeNewsWire • 05/12/23

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

GlobeNewsWire • 03/30/23

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

PRNewsWire • 03/23/23

Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

Zacks Investment Research • 03/23/23

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

GlobeNewsWire • 03/01/23

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

GlobeNewsWire • 02/06/23

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

GlobeNewsWire • 02/02/23

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

GlobeNewsWire • 01/26/23

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

GlobeNewsWire • 12/10/22